SYSTEMATIC REVIEW article
Front. Cardiovasc. Med.
Sec. Lipids in Cardiovascular Disease
This article is part of the Research TopicNew Drugs in Lipid Lowering TherapyView all 6 articles
Efficacy and Safety of Lipoprotein(a)-Targeted Therapeutics: A systematic review and network meta-analysis
Provisionally accepted
- 1Guang'an People's Hospital, Guang'an, China
- 2Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 3Sichuan Province Key Laboratory of Personalized Drug Therapy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
- 4Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Lipoprotein(a)–targeted therapies are emerging approaches for lowering lipoprotein(a) [lp(a)]. Objective We conducted a systematic review and network meta-analysis to evaluate the efficacy and safety of lipoprotein(a)–targeted therapies in patients. Methods We searched PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to May 6, 2025, for randomized controlled trials (RCTs) with intervention duration of at least 12 weeks. The primary outcomes were percentage and absolute changes in Lp(a). Secondary outcomes included changes in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), and safety outcomes including adverse events (AEs), serious adverse events (SAEs), and injection-site reactions. A frequentist framework network meta-analysis was performed. Results Nine studies involving 1432 participants were included. All six Lp(a)-targeted therapies significantly reduced Lp(a) levels. Compared with placebo, Olpasiran was the most effective therapy for both percentage (mean difference:-92.06, 95% [-109.80; -74.32], P-score: 0.94) and absolute reductions (-250.70 [-262.04; -239.36], P-score: 0.99), followed by Zerlasiran (-78.33 [-92.18; -64.48], P-score: 0.70), (-205.63 [-217.24; - 194.03], P-score: 0.76). In between-drug comparisons, Olpasiran was superior to Pelacarsen. Both Olpasiran and Zerlasiran were associated with improved LDL-C and apoB concentrations. Zerlasiran, Lepodisiran, and Pelacarsen were found to increase the risk of injection-site reactions. Conclusions Lp(a)-targeted therapies achieved substantial reductions in Lp(a). Olpasiran was the most effective agent in lowering Lp(a) levels. These therapies also improved LDL-C and apoB. The majority of Lp(a)-targeted therapies demonstrate generally favorable safety profiles; However, injection-site reactions, particularly with Zerlasiran, warrant careful consideration.
Keywords: antisense oligonucleotides, Lipoprotein(a), lipoprotein(a)-targeted therapies, Muvalaplin, Network meta-analysis, small interfering RNA
Received: 01 Dec 2025; Accepted: 16 Feb 2026.
Copyright: © 2026 Hu, Wang, Zhang, Jiang, Deng, Long and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Enwu Long
Song Liu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.